Compare Enveric Biosciences Inc (ENVB) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs M&T Bank Corporation — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.80M), while M&T Bank Corporation trades at $216.43 (market cap $31.42B). The key difference: M&T Bank Corporation is far larger — about 4620.6× Enveric Biosciences Inc's market cap, and M&T Bank Corporation pays a 2.76% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and M&T Bank Corporation for 100 Days on average.
| ENVB | MTB | |
|---|---|---|
Market Cap | $6.80M | $31.42B |
Volume | 64,867 | 1,438,219 |
Sector | Health | Financials |
52-Week High | $10.80 | $254.09 |
52-Week Low | $1.27 | $178.63 |
Typical Hold Time | 14 Days | 100 Days |
Enterprise Value | -$1.49M | $47.77B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
M&T Bank (MTB) trades at $216.60, down 0.98% with a bearish technical outlook. The stock shows strong fundamentals with a P/E of 11.52 and net income margin of 30.85%, supported by three consecutive quarterly earnings beats. Recent news highlights dividend strength and branch expansion, while cash flow trends show operational stability despite negative net cash flow in 2025.
MTB presents a value opportunity with attractive valuation metrics and consistent profitability, though technical weakness and declining cash flow warrant caution. Analyst consensus targets $258.92 (19.5% upside) with 31% buy ratings, but bearish technical signals and rising debt levels pose near-term risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
